NEWARK, U.S.A. and NANJING, China, May 15, 2024 — Biosion, a global, clinical-stage biotechnology company, today presented key additional preclinical data of its anti-SIRPα antagonistic antibody BSI-082 at the PEGS Boston Summit.
The poster presentation entitled: ”Preclinical characterization of a highly differentiated pan-allele anti-SIRPα antibody BSI-082 that targets the myeloid immune checkpoint”, includes data from the BSI-082 preclinical study and displays encouraging results in the animal models with multiple combination therapies.
Specifically, BSI-082 exhibited higher binding affinity and broader population coverage than the BI-765063 analog. In addition, BSI-082 significantly enhanced anti-tumor efficacy in animal models with multiple combination therapies. BSI-082 exhibited excellent PK characteristics and was well-tolerated with a NOAEL of 250 mg/kg in pre-clinical TOX studies.
“We are encouraged by the potential therapeutic impact we have seen thus far, which supports the use of BSI-082 as a meaningful therapeutic option for patients with solid tumors,” said Mingjiu Chen, Ph.D., Founder and Chief Executive Officer of Biosion, Inc. “BSI-082 was developed through our proprietary H³ antibody discovery platform and received US IND clearance in Jan 2024. This achievement highlights the capability of our technology platform in developing novel antibody-based therapeutics."
About BSI-082
BSI-082 is a best-in-class,highly differentiated, fully human anti-SIRPα antagonistic monoclonal antibody. It shows strong binding activity to huSIRPα variants V1/V2/V8, thus can cover over 90% of the human population. BSI-082 specifically binds to SIRPα and SIRPβ but not to SIRPγ, and blocks the interaction of SIRPα to CD47, the “don’t eat me” signal expressed on a wide variety of tumors. Blocking SIRPα enables tumor associated macrophages and dendritic cells to resume their phagocytoxic activity against tumor cells while avoiding the broad toxicity profile that many CD47-targeting therapies have encountered. BSI-082 demonstrated potent in vivo anti-tumor efficacy when combined with mAbs against tumor-associated antigens in multiple animal models.
About Biosion
Biosion is a global, clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes with immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform. Biosion’s lead asset, Bosakitug (BSI-045B/TQC2731), an anti-TSLP mAb, is currently in phase II for severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps (CRSwNP), with another 6 partnered assets in phase I/II. Biosion has operations in the US, China and Australia. For more information, please visit www.Biosion.com.
BIOSION ALL RIGHTS RESERVED.
NEWARK, U.S.A. and NANJING, China, May 15, 2024 — Biosion, a global, clinical-stage biotechnology company, today presented key additional preclinical data of its anti-SIRPα antagonistic antibody BSI-082 at the PEGS Boston Summit.
The poster presentation entitled: ”Preclinical characterization of a highly differentiated pan-allele anti-SIRPα antibody BSI-082 that targets the myeloid immune checkpoint”, includes data from the BSI-082 preclinical study and displays encouraging results in the animal models with multiple combination therapies.
Specifically, BSI-082 exhibited higher binding affinity and broader population coverage than the BI-765063 analog. In addition, BSI-082 significantly enhanced anti-tumor efficacy in animal models with multiple combination therapies. BSI-082 exhibited excellent PK characteristics and was well-tolerated with a NOAEL of 250 mg/kg in pre-clinical TOX studies.
“We are encouraged by the potential therapeutic impact we have seen thus far, which supports the use of BSI-082 as a meaningful therapeutic option for patients with solid tumors,” said Mingjiu Chen, Ph.D., Founder and Chief Executive Officer of Biosion, Inc. “BSI-082 was developed through our proprietary H³ antibody discovery platform and received US IND clearance in Jan 2024. This achievement highlights the capability of our technology platform in developing novel antibody-based therapeutics."
About BSI-082
BSI-082 is a best-in-class,highly differentiated, fully human anti-SIRPα antagonistic monoclonal antibody. It shows strong binding activity to huSIRPα variants V1/V2/V8, thus can cover over 90% of the human population. BSI-082 specifically binds to SIRPα and SIRPβ but not to SIRPγ, and blocks the interaction of SIRPα to CD47, the “don’t eat me” signal expressed on a wide variety of tumors. Blocking SIRPα enables tumor associated macrophages and dendritic cells to resume their phagocytoxic activity against tumor cells while avoiding the broad toxicity profile that many CD47-targeting therapies have encountered. BSI-082 demonstrated potent in vivo anti-tumor efficacy when combined with mAbs against tumor-associated antigens in multiple animal models.
About Biosion
Biosion is a global, clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes with immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform. Biosion’s lead asset, Bosakitug (BSI-045B/TQC2731), an anti-TSLP mAb, is currently in phase II for severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps (CRSwNP), with another 6 partnered assets in phase I/II. Biosion has operations in the US, China and Australia. For more information, please visit www.Biosion.com.
BIOSION ALL RIGHTS RESERVED.